CardioAssure — Control-Point Telemetry Architecture

FDA's cybersecurity guidance keeps converging on one idea — and most security models in this space aren't built for it yet.

Medical device cybersecurity has a new center of gravity. FDA's Section 524B and its 2025–2026 guidance keep returning to the same themes: secure-by-design, attack surface reduction, and resilience across connected ecosystems — not just detecting threats after they appear.

That shift raises a question worth sitting with. Most security models assume communication has already begun, then work to catch what shouldn't be there. But as telemetry pathways multiply across implants, monitors, mobile apps, and cloud services — and as AI-assisted attack tooling gets faster at finding exploitable gaps — the more useful question may come earlier: should this telemetry session be permitted to start at all?

Architectures built around explicit, per-session authorization — verifying identity, workflow context, and policy conditions before any communication path opens, and denying by default otherwise — look increasingly aligned with where FDA guidance is heading.

It may be a quieter shift than it sounds, but a meaningful one for how connected medical devices get secured going forward.

Telemetry that asks permission,
not forgiveness.

AI is compressing the time between vulnerability discovery and exploitation — changing the calculus for detection-based security.

What CardioAssure means for your role

Regulatory leaders

Engineering leaders

Security leaders

FDA has raised the bar on what you must demonstrate — and document. FDA has raised the bar — without giving your team more room in the implant. FDA has raised the bar. The threat landscape is accelerating at the same time.

Submissions that can't show their work Expanded scope, same hardware constraints Expanded FDA expectations

A widening evidence gap A constrained implant An accelerating threat curve

Lifecycle obligations, not a single filing Validation scope creep Detection alone is no longer enough

One control point. Every session generates evidence. One control point. The implant stays untouched. One control point. Every session explicitly authorized.

Identity determination

Workflow validation

Port authorization & gating

Audit logging

A traceability matrix your submission can cite directly. Evidence enablement, not compliance substitution. Controls mapped to what reviewers actually ask for.

Conceived before Section 524B. Aligned by design, not by response.

Priority date filed

Section 524B enacted

FDA guidance updated, then reissued

Two patents granted

Where the conversation on medical-device cybersecurity is heading.

Medical Device Cybersecurity Is Shifting — Section 524B and What Comes Next

Why "Detect and Respond" Isn't Built for What's Coming Next

Technical documentation for engineering and compliance teams.

AI and the Future of Medical Device Cybersecurity

Technical & Compliance Overview

Reference Architecture Whitepaper

We’re at an early, exploratory stage.

Thank you — we’ll be in touch.

Telemetry that asks permission,not forgiveness.